Celsion Corp. (NASDAQ: CLSN) stock gains by 2.62% in the current market trading. Celsion is a properly connected, medical biotechnology firm dedicated to developing a portfolio of novel cancer treatments, such as immunotherapies and DNA-based medicines, as well as a platform for the development of nucleic acid vaccines, which is presently focusing on SARS-CoV2.
CLSN stock’ Significant Development
Celsion Corporation reported preliminary in vivo data indicating that immunizing BALB/c mice with the Company’s next-generation PLACCINE DNA vaccine platform resulted in the development of antibodies and a cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2. In a viral neutralization experiment, antibodies to the SARS-CoV-2 spike antigen also inhibited infection of cultured cells. PLACCINE’s capacity to protect against SARS-CoV-2 exposure is predicted by the generation of antibodies, and the vaccine’s ability to destroy SARS-CoV-2-infected cells is demonstrated by the elicitation of cytotoxic T-cell responses.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
These findings show that Celsion’s PLACCINE DNA vaccine, which is designed to give broad-spectrum protection and resistance to variations, may be immunogenic. It works by combining several viral antigens to increase vaccine durability at storage temperatures of 4° C and higher, as well as to make vaccine manufacture cheaper and easier. Celsion plans to present these findings at the International Vaccines Conference in October 2021.
Khursheed Anwer, Ph.D., Celsion’s Executive Vice President and Chief Science Officer stated.
They’re working on an intramuscular vaccination that uses a customized synthetic delivery mechanism to deliver large amounts of viral proteins and trigger the appropriate immune response. The administration of this formulation does not necessitate the use of a separate delivery method, such as electroporation. They’re excited about the immunogenicity results from our recent preclinical research, and they’ll keep you updated on developments from current in vivo trials to improve the PLACCINE DNA vaccine’s efficacy through vector design, delivery method, dosage levels and dosing frequency, and adjuvant quality. Their initial aim, if they are successful, is to confirm their program with IND-enabling trials.
